These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38467181)

  • 1. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
    Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
    Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
    Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.
    Carbone C; Piro G; Agostini A; Delfino P; De Sanctis F; Nasca V; Spallotta F; Sette C; Martini M; Ugel S; Corbo V; Cappello P; Bria E; Scarpa A; Tortora G
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL10 mediates CD8
    Yan W; Qiu L; Yang M; Xu A; Ma M; Yuan Q; Ma X; Liang W; Li X; Lu Y
    Cancer Lett; 2023 Jul; 567():216263. PubMed ID: 37354983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
    Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.
    Doleschel D; Hoff S; Koletnik S; Rix A; Zopf D; Kiessling F; Lederle W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):288. PubMed ID: 34517894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8
    Huang MY; Chen YC; Lyu WY; He XY; Ye ZH; Huang CY; He XL; Chen X; Chen X; Zhang B; Kai G; Zhang X; Li T; Huang M; Lu JJ
    Pharmacol Res; 2023 Dec; 198():106988. PubMed ID: 37984507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.